Keynote Address: New Poverty-Related Neglected Diseases (‘The NTDs’) by Hotez, Peter
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Research Retreat 
2017 UMass Center for Clinical and 
Translational Science Research Retreat 
May 16th, 9:45 AM 
Keynote Address: New Poverty-Related Neglected Diseases (‘The 
NTDs’) 
Peter Hotez 
Baylor College of Medicine 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat 
 Part of the International Public Health Commons, Translational Medical Research Commons, and the 
Tropical Medicine Commons 
Hotez P. (2017). Keynote Address: New Poverty-Related Neglected Diseases (‘The NTDs’). UMass Center 
for Clinical and Translational Science Research Retreat. Retrieved from 
https://escholarship.umassmed.edu/cts_retreat/2017/program/4 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
                                                                                                                                                                                                                                                          
New Poverty-Related Neglected 
Diseases (‘The NTDs’) 
 
Peter Hotez, M.D., Ph.D. 
 
Texas Children’s Hospital Endowed 
Chair in Tropical Pediatrics 
 
Dean, National School of Tropical Medicine  
at Baylor College of Medicine 
 














Page  2 





Page  3 
















Page  4 
xxx00.#####.ppt  6/28/17 9:14 PM 
Page  5 




The Global Burden of Disease Study	
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“Other Diseases” 
The Neglected Tropical Diseases 
•  13-14 tropical infections: 
- Highly prevalent among the poor 




- Disabling (growth delays, blindness or 
disfigurement) 
- Stigmatizing 
- Poverty promoting  
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Dengue and other 
   arboviruses  
Food-borne 
   trematodiases 
Lymphatic Filariasis 










 Trachoma   
Cysticercosis   
Echinococcosis 
Hansen’s Disease 
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NTDs and Girls & Women 
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Ascariasis, Trichuriasis, Hookworm, Schistosomiasis,  
LF, Onchocerciasis, Trachoma 
Hotez	PJ	et	al.		Lancet		2009	
The	BoHom	Billion	Suﬀers	from	MulEple	NTDs!			
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NTD Scale up with the U.S. Government 
+ Drug Donations from  
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USAID	NTD	Program	
>450	million	People	Rx:	Elimina@on	of	some	NTDs	
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Case detection + 











Leprosy (Hansen’s Disease) 
Source: GBD 2015 and GBD 2013 
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Case detection + 





Losing the Battle:  
Vector-borne Neglected Diseases 
 Arthropods 
 Snails 
Zoonotic Neglected Diseases 
 Viral Diseases 
Source: GBD 2015 and GBD 2013 
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Are we playing 
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POVERTY:  “Blue Marble Health” 
- Neglected 
diseases of the 
poor living amidst 
wealth 
- A new framework 
for global science 
policy and the 
poverty-related 
diseases 
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Blue Marble Health: 
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Chagas disease in Argentina, Brazil, Mexico 




•  Ranking By Chagas 
- 1. Argentina 1.5 million 
- 2. Brazil 1.2 million 
- 3. Mexico 0.9 million 
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Brazil and Blue Marble Health 
Poverty	&	Disease	NE	Brazil:		
Schistosomiasis,	Leishmaniasis,	Chagas,	Dengue	
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Zika Microcephaly cases in NE Brazil 
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Poverty in Northeastern Brazil 
Salvador	de	Bahia	Recife	
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Spread of Zika in the Americas 
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Hotez PJ “Zika is Coming”  
The New York Times April 9, 2016 
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WAR & POLITICAL DESTABILIZATION:  Ebola	
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Vaccinating Against The 
Anthropocene’s NTDs 
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Rino Rappuoli: Reverse Vaccinology 
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Reverse vaccinology as a ‘holy grail’ 
for complex eukaryotic organisms 
- Large genomes of similar 
complexity to human 
genome 
- Inadequacy of bacterial 
expression systems for 
eukaryotic antigens 
- Low throughput not high 
throughput 
- Deficiencies in animal 
models 
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Goals of Anti-schistosome Vaccine 
•  Worm burden reduction 
•  Egg reduction 
•  Reduced end-organ 
pathology 
•  Reduction in inflammation 
•  Reduction in anemia and 
malnutrition 
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Immunomics Approach: 
Schistosome protein microarrays 
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Immune localization of Sm-TSP-2 
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Suppression of tsp-2 mRNA expression results 
in impaired tegument turnover in vitro	
Tran	et	al.	PLoS	Path	2010	
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Intestinal Schistosomiasis Vaccine 
The	Schistosome	Tetraspanins	
Entering phase 1 trials – Baylor VTEU 
Entering phase 1 trials – Baylor VTEU 
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The Rise of Emerging + Neglected Diseases 
in the “New Texas” 
•  Leading TX NTDs 
- Toxocariasis  700,000 
- Trichomoniasis 450,000 
- Chagas disease 37,000 
- WNV 183-1,900 
- Intestinal protozoan 1,000 
- Cysticercosis 195-754 
- Murine Typhus >100 
- Dengue, Zika, Chik 
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•  Preclinical Efficacy: 
- Pilot studies were performed to evaluate efficacy of 
recombinant Tc24 combined with imiquimod or MPLA when 
used as a preventative vaccine 
•  Preliminary Results 
• Reduce parasitemia  
• Increase survival during acute phase 
• Antigen specific IgG2a 
• Antigen specific IFNγ 
• Reduced cardiac parasite burden 
53 
ADVANCES IN A THERAPEUTIC CHAGAS VACCINE INITIATIVE 
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Western Blot comparison of Tc24-WT (A), Tc24-C2 (B), and Tc24-C4 (C) purified proteins. Lanes 
1-3: Non-Reduced. Lane 4: SeeBlue Plus Molecular Weight Marker. Lanes 5-7 Reduced. Lanes 1,5: 
Sample before size-exclusion chromatography (SEC) 8 µg load. Lanes 2,6: Post SEC low load (3 
µg). Lanes 3,7: Post SEC high load (8 µg). Detection was performed using mouse polyclonal 
antibody against Tc24 expressed in Pichia pastoris as primary antibody diluted 1:2,500 in PBST and 
an alkaline phosphatase conjugated goat anti-mouse secondary antibody diluted 1:7,500 in PBST. 
Oligomer Formation: Solving the problem? 
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Structural comparison of Tc24 constructs. a) Circular Dichroism (CD). Far UV CD spectrum of different 
constructs of Tc24 were taken on a Jasco J-1500. All tested Tc24 protein have a virtual identical CD profile 
with overlapping spectra. Negative peaks at 222 nm and 208 nm and a positive peak at 193 nm indicate that 
Tc24 is an α-helical protein. b) Thermal melting profile of Tc24-WT and Tc24-C4 measured using Protein 
Thermal Shift™ kit (Life Technologies). 
Maintaining secondary/tertiary structures 
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